PLN and hydrops fetalis: Overall, our PLN-ASO experiments suggest potential to further develop such a therapeutic strategy as both a personalized medicine for PLN mutation carriers and as a more generalized treatment for patients with DCM or HF with reduced ejection fraction (HFrEF).